The more accurate description of these numbers is they represent what HCR will cost these companies in the short term. Costs for most, though perhaps not device companies, will be offset by added customers once UC kicks in.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.